Current status and research hotspots of cardio-oncology based on bibliometrics

Mengjuan LI; Ying LIU; Yanli ZHANG; Mengyao LIU; Yanan XUE; Liping SU; Xiujie ZHANG; Tieying SHI; Fengqi FANG; Jiwei LIU; Yunlong XIA

doi:10.19401/j.cnki.1007-3639.2022.10.001

您当前的位置：

首页 >

文章列表页 >

Current status and research hotspots of cardio-oncology based on bibliometrics

Specialists'Article | 更新时间：2025-12-31

- Current status and research hotspots of cardio-oncology based on bibliometrics
- China Oncology Vol. 32, Issue 10, Pages: 925-935(2022)
- 作者机构：
  
  1. 大连医科大学附属第一医院心内科，辽宁大连 116021
  2. 大连医科大学附属第一医院肿瘤科，辽宁大连 116021
  3. 大连医科大学附属第一医院护理部，辽宁大连 116021
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2022.10.001
  CLC： R737
- Received：05 August 2022，
  
  Revised：2022-10-17，
  
  Published Online：30 October 2022，
- 稿件说明：
移动端阅览
Mengjuan LI, Ying LIU, Yanli ZHANG, et al. Current status and research hotspots of cardio-oncology based on bibliometrics[J]. China Oncology, 2022, 32(10): 925-935.
DOI：

Mengjuan LI, Ying LIU, Yanli ZHANG, et al. Current status and research hotspots of cardio-oncology based on bibliometrics[J]. China Oncology, 2022, 32(10): 925-935. DOI： 10.19401/j.cnki.1007-3639.2022.10.001.

摘要

背景与目的：

肿瘤心脏病学作为一门新兴的交叉学科，主要关注与肿瘤治疗相关的心血管毒性的管理，在过去十年取得了长足的发展。本研究利用文献计

量学方法分析国内外肿瘤心脏病学领域热点和趋势，为相关研究提供参考。

方法：

基于Web of Science核心数据库和中国知网即中国知识基础设施工程（China National Knowledge Infrastructure，CNKI），使用CiteSpace软件对2012—2022年国内外肿瘤心脏病学领域研究的发文量、国家、机构、作者、高被引文献、关键词进行分析。

结果：

筛选后共纳入4 287篇英文文献，1 165篇中文文献。目前国外肿瘤心脏病学领域的文献数量呈快速增长趋势，而中国以2016年为界，产生了“缓慢发展期”和“快速发展期”。美国是Web of Science中发文量最多的国家，约占总数的34.21%，其次是中国、意大利等。国内外发文量最多的机构分别是得克萨斯大学MD安德森癌症中心（The University of Texas MD Anderson Cancer Center）和大连医科大学附属第一医院。国外以Bonnie KY、Ana Barac、Paaladinesh Thavendiranathan等为主要贡献者，国内以夏云龙、张宇辉、程蕾蕾等为主要贡献者。Web of Science被引频次最高的文献是来自欧洲心脏病学会的关于癌症治疗和心血管毒性的立场声明，反映了专业协会的指南和共识常作为一个学科中被广泛引用的文献可直接影响临床实践。国外出现频次最高的关键词是“heart failure”、“breast cancer”、“cardiotoxicity”等，国内出现频次最高的关键词是“心脏毒性”、“心脏肿瘤”、“阿霉素”等。“immune checkpoint inhibitors”、“免疫检查点抑制剂相关心肌炎”是近3年的突现词，从分析结果可以看出，国外主要关注肿瘤心脏病的发生机制、肿瘤心脏病的防治，国内则更多地关注抗肿瘤治疗引起的心脏毒性，如“化疗”、“阿霉素”、“多柔比星”、“蒽环类”等。

结论：

研究热点主要集中于抗肿瘤治疗引起的心脏毒性、肿瘤心脏病的防治、肿瘤心脏病的筛查与诊断等；建立多学科参与的诊疗模式，关注免疫检查点抑制剂相关心肌炎及肿瘤心脏病的全程管理是未来关注的方向。

Abstract

关键词

Keywords

references

夏云龙 , 张运 . 萌芽中的肿瘤心脏病学: 机遇与挑战 [J ] . 中华心血管病杂志 , 2017 ( 3 ): 182 - 185 .

XIA Y L , ZHANG Y . Oncocardiology in the bud: opportunities and challenges [J ] . Chin J Cardiol , 2017 ( 3 ): 182 - 185 .

DE BOER R A , MEIJERS W C , VAN DER MEER P , et al. Cancer and heart disease: associations and relations [J ] . Eur J Heart Fail , 2019 , 21 ( 12 ): 1515 - 1525 . DOI: 10.1002/ejhf.1539 http://doi.org/10.1002/ejhf.1539

陈悦 , 陈超美 , 刘则渊 , 等 . CiteSpace知识图谱的方法论功能 [J ] . 科学学研究 , 2015 , 33 ( 2 ): 242 - 253 .

CHEN Y , CHEN C M , LIU Z Y , et al. The methodology function of CiteSpace mapping knowledge domains [J ] . Stud Sci Sci , 2015 , 33 ( 2 ): 242 - 253 .

刘斌亮 , 王延风 , 马飞 . 从肿瘤学出发, 浅谈肿瘤心脏病学的发展、现状与挑战 [J ] . 中国心血管杂志 , 2018 , 23 ( 5 ): 357 - 359 .

LIU B L , WANG Y F , MA F . Starting from the oncology, analyze the development, situation and challenges of Cardio-Oncology [J ] . Chin J Cardiovasc Med , 2018 , 23 ( 5 ): 357 - 359 .

ZHANG Y , LIU Y , XIA Y . Dedicated to cardio-oncology [J ] . Eur Heart J , 2020 , 41 ( 8 ): 907 - 909 . DOI: 10.1093/eurheartj/ehaa064 http://doi.org/10.1093/eurheartj/ehaa064

KY B . JACC: CardioOncology: poised to serve a maturing, collaborative field [J ] . JACC CardioOncol , 2019 , 1 ( 1 ): 131 - 132 . DOI: 10.1016/j.jaccao.2019.06.001 http://doi.org/10.1016/j.jaccao.2019.06.001 https://linkinghub.elsevier.com/retrieve/pii/S2666087319300018 https://linkinghub.elsevier.com/retrieve/pii/S2666087319300018

LIU Y , ZHANG Y L , LIU J W , et al. Emergence, development, and future of cardio-oncology in China [J ] . Chin Med J (Engl) , 2018 , 131 ( 21 ): 2640 - 2644 .

ZHANG Y H , ZHANG Z R , LIU Y , et al. Cardio-oncology in China: we are on the go! [J ] . JACC CardioOncol , 2020 , 2 ( 1 ): 139 - 143 . DOI: 10.1016/j.jaccao.2020.02.007 http://doi.org/10.1016/j.jaccao.2020.02.007 https://linkinghub.elsevier.com/retrieve/pii/S2666087320300156 https://linkinghub.elsevier.com/retrieve/pii/S2666087320300156

ZAMORANO J L , LANCELLOTTI P , RODRIGUEZ MUÑOZ D , et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) [J ] . Eur Heart J , 2016 , 37 ( 36 ): 2768 - 2801 . DOI: 10.1093/eurheartj/ehw211 http://doi.org/10.1093/eurheartj/ehw211 https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehw211 https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehw211

ARMENIAN S H , LACCHETTI C , BARAC A , et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline [J ] . J Clin Oncol , 2017 , 35 ( 8 ): 893 - 911 . DOI: 10.1200/JCO.2016.70.5400 http://doi.org/10.1200/JCO.2016.70.5400

PLANA J C , GALDERISI M , BARAC A , et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging [J ] . J Am Soc Echocardiogr , 2014 , 27 ( 9 ): 911 - 939 . DOI: 10.1016/j.echo.2014.07.012 http://doi.org/10.1016/j.echo.2014.07.012 https://linkinghub.elsevier.com/retrieve/pii/S0894731714005343 https://linkinghub.elsevier.com/retrieve/pii/S0894731714005343

CARDINALE D , COLOMBO A , BACCHIANI G , et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy [J ] . Circulation , 2015 , 131 ( 22 ): 1981 - 1988 . DOI: 10.1161/CIRCULATIONAHA.114.013777 http://doi.org/10.1161/CIRCULATIONAHA.114.013777

JOHNSON D B , BALKO J M , COMPTON M L , et al. Fulminant myocarditis with combination immune checkpoint blockade [J ] . N Engl J Med , 2016 , 375 ( 18 ): 1749 - 1755 . DOI: 10.1056/NEJMoa1609214 http://doi.org/10.1056/NEJMoa1609214 http://www.nejm.org/doi/10.1056/NEJMoa1609214 http://www.nejm.org/doi/10.1056/NEJMoa1609214

GULATI G , HECK S L , REE A H , et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol [J ] . Eur Heart J , 2016 , 37 ( 21 ): 1671 - 1680 . DOI: 10.1093/eurheartj/ehw022 http://doi.org/10.1093/eurheartj/ehw022

THAVENDIRANATHAN P , POULIN F , LIM K D , et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review [J ] . J Am Coll Cardiol , 2014 , 63 ( 25 ): 2751 - 2768 . DOI: 10.1016/j.jacc.2014.01.073 http://doi.org/10.1016/j.jacc.2014.01.073 https://linkinghub.elsevier.com/retrieve/pii/S073510971401660X https://linkinghub.elsevier.com/retrieve/pii/S073510971401660X

ZHANG S , LIU X B , BAWA-KHALFE T , et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity [J ] . Nat Med , 2012 , 18 ( 11 ): 1639 - 1642 . DOI: 10.1038/nm.2919 http://doi.org/10.1038/nm.2919

SAWAYA H , SEBAG I A , PLANA J C , et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab [J ] . Circ Cardiovasc Imaging , 2012 , 5 ( 5 ): 596 - 603 . DOI: 10.1161/CIRCIMAGING.112.973321 http://doi.org/10.1161/CIRCIMAGING.112.973321

CURIGLIANO G , LENIHAN D , FRADLEY M , et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations [J ] . Ann Oncol , 2020 , 31 ( 2 ): 171 - 190 . DOI: S0923-7534(19)36080-6 http://doi.org/S0923-7534(19)36080-6

LYON A R , YOUSAF N , BATTISTI N M L , et al. Immune checkpoint inhibitors and cardiovascular toxicity [J ] . Lancet Oncol , 2018 , 19 ( 9 ): e447 - e458 . DOI: 10.1016/S1470-2045(18)30457-1 http://doi.org/10.1016/S1470-2045(18)30457-1 https://linkinghub.elsevier.com/retrieve/pii/S1470204518304571 https://linkinghub.elsevier.com/retrieve/pii/S1470204518304571

中国抗癌协会整合肿瘤心脏病学分会中华医学会心血管病学分会肿瘤心脏病学学组中国医师协会心血管内科医师分会肿瘤心脏病学专业委员会 , 等 . 免疫检查点抑制剂相关心肌炎监测与管理中国专家共识(2020版) [J ] . 中国肿瘤临床 , 2020 , 47 ( 20 ): 1027 - 1038 .

Society of Integrative Cardio-Oncology China Anti-Cancer Association, the Cardio-Oncology Group of the Chinese Society of Cardiovascular Diseases of Chinese Medical Association, Chinese College of Cardiovascular Physicians Specialized Committee on Cardio-Oncology Chinese Medical Doctor Association , et al. Chinese expert consensus on the surveillance and management of immune checkpoint inhibitor-related myocarditis (2020 version) [J ] . Chin J Clin Oncol , 2020 , 47 ( 20 ): 1027 - 1038 .

马军 , 秦叔逵 , 沈志祥 . 蒽环类药物心脏毒性防治指南(2013年版) [J ] . 临床肿瘤学杂志 , 2013 , 18 ( 10 ): 925 - 934 .

MA J , QIN S K , SHEN Z X . Guidelines for the prevention and treatment of cardiotoxicity of anthracycline drugs (2013 edition) [J ] . Chin Clin Oncol , 2013 , 18 ( 10 ): 925 - 934 .

李艳阳 , 王云姣 , 韩德军 , 等 . 基于数据挖掘的中医药治疗抗肿瘤药物心脏毒性用药规律研究 [J ] . 中国中医基础医学杂志 , 2022 , 28 ( 1 ): 138 - 141 .

LI Y Y , WANG Y J , HAN D J , et al. Research on medication rule of cardiotoxicity with traditional Chinese medicine based on data mining [J ] . J Basic Chin Med , 2022 , 28 ( 1 ): 138 - 141 .

薛静娴 , 卞卫和 , 姚昶 . 中药汤剂治疗乳腺癌患者蒽环类药物化疗心脏毒性的meta分析 [J ] . 世界科学技术-中医药现代化 , 2018 , 20 ( 6 ): 922 - 928 .

XUE J X , BIAN W H , YAO C . Meta-analysis of curative effects of traditional Chinese herbal decoction on breast carcinoma patients in doxorubicin-induced cardiotoxicity [J ] . Mod Tradit Chin Med Mater Med World Sci Technol , 2018 , 20 ( 6 ): 922 - 928 .

BROWN S A . Preventive cardio-oncology: the time has come [J ] . Front Cardiovasc Med , 2019 , 6 : 187 . DOI: 10.3389/fcvm.2019.00187 http://doi.org/10.3389/fcvm.2019.00187 https://www.frontiersin.org/article/10.3389/fcvm.2019.00187/full https://www.frontiersin.org/article/10.3389/fcvm.2019.00187/full

LYON A R , DENT S , STANWAY S , et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society [J ] . Eur J Heart Fail , 2020 , 22 ( 11 ): 1945 - 1960 . DOI: 10.1002/ejhf.1920 http://doi.org/10.1002/ejhf.1920 https://onlinelibrary.wiley.com/doi/10.1002/ejhf.1920 https://onlinelibrary.wiley.com/doi/10.1002/ejhf.1920

LYON A R , LÓPEZ-FERNÁNDEZ T , COUCH L S , et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) developed by the task force on cardio-oncology of the European Society of Cardiology (ESC) [J ] . Eur Heart J , 2022 .

PLANA J C , THAVENDIRANATHAN P , BUCCIARELLI-DUCCI C , et al. Multi-modality imaging in the assessment of cardiovascular toxicity in the cancer patient [J ] . JACC Cardiovasc Imaging , 2018 , 11 ( 8 ): 1173 - 1186 . DOI: 10.1016/j.jcmg.2018.06.003 http://doi.org/10.1016/j.jcmg.2018.06.003 https://linkinghub.elsevier.com/retrieve/pii/S1936878X18305205 https://linkinghub.elsevier.com/retrieve/pii/S1936878X18305205

ARMSTRONG G T , KAWASHIMA T , LEISENRING W , et al. Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study [J ] . J Clin Oncol , 2014 , 32 ( 12 ): 1218 - 1227 . DOI: 10.1200/JCO.2013.51.1055 http://doi.org/10.1200/JCO.2013.51.1055

Views

2529

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Current status and controversy of cardio-oncology in breast cancer

Current status and focus of breast reconstruction research in China and abroad: a bibliometric study

Value of global longitudinal strain in assessing radiation-induced heart disease in breast cancer: systematic review and meta-analysis

Chinese consensus of cardio-oncology in breast cancer

Different preventive effects of four cardioprotective agents on mice with adriamycin-induced cardiotoxicity

Related Author

杨艺琦

吴　昊

殷咏梅

Jiong WU

Zhimin SHAO

Guangyu LIU

Ayong CAO

Benlong YANG

Related Institution

南京医科大学

南京医科大学第一附属医院肿瘤科

Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

Graduate School, Hebei Medical University

Fourth Department of Oncology, Hebei General Hospital

AI问答

⁰